Adolescent Δ 9-Tetrahydrocannabinol Exposure Alters WIN55,212-2 Self-Administration in Adult Rats

Neuropsychopharmacology

Volumn 41, Issue 5, 2016, Pages 1416-1426

  Scherma, Maria ^a   Dessì, Christian ^a   Muntoni, Anna Lisa ^a,b   Lecca, Salvatore ^a   Satta, Valentina ^a   Luchicchi, Antonio ^a   Pistis, Marco ^a,b   Panlilio, Leigh V ^c   Fattore, Liana ^a,b   Goldberg, Steven R ^c   Fratta, Walter ^a   Fadda, Paola ^a  

^a UNIVERSITY OF CAGLIARI   (Italy)

^b CNR   (Italy)

^c Behavioral Neuroscience Research Branch   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; DOPAMINE; DRONABINOL; BENZOXAZINE DERIVATIVE; CANNABINOID 1 RECEPTOR; MORPHOLINE DERIVATIVE; NAPHTHALENE DERIVATIVE;

ADOLESCENT; ADULT; ANIMAL EXPERIMENT; ARTICLE; CANNABIS USE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DRUG MECHANISM; DRUG SELF ADMINISTRATION; ELEVATED PLUS MAZE TEST; FIRING RATE; LOCOMOTION; MALE; MESOLIMBIC DOPAMINERGIC SYSTEM; NERVE CELL; NERVOUS SYSTEM FUNCTION; NONHUMAN; NUCLEUS ACCUMBENS SHELL; PREPULSE INHIBITION; PRIORITY JOURNAL; RAT; REWARD; SUCROSE PREFERENCE TEST; VENTRAL TEGMENTUM; AGONISTS; ANIMAL; ANIMAL BEHAVIOR; DRUG EFFECTS; METABOLISM; NUCLEUS ACCUMBENS; PHYSIOLOGY;

ANIMALS; BEHAVIOR, ANIMAL; BENZOXAZINES; DOPAMINE; DOPAMINERGIC NEURONS; DRONABINOL; MALE; MORPHOLINES; NAPHTHALENES; NUCLEUS ACCUMBENS; RATS; RECEPTOR, CANNABINOID, CB1; SELF ADMINISTRATION; VENTRAL TEGMENTAL AREA;

EID: 84960862345     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2015.295     Document Type: Article

References (64)

1. Amchova P, Kucerova J, Giugliano V, Babinska Z, Zanda MT, Scherma M et al (2014). Enhanced self-administration of the CB1 receptor agonist WIN55,212-2 in olfactory bulbectomized rats: evaluation of possible serotonergic and dopaminergic underlying mechanisms. Front Pharmacol 5: 44.
2. Bassareo V, Di Chiara G (1999). Modulation of feeding-induced activation of mesolimbic dopamine transmission by appetitive stimuli and its relation to motivational state. Eur J Neurosci 11: 4389-4397.
3. Battistella G, Fornari E, Annoni JM, Chtioui H, Dao K, Fabritius M et al (2014). Long-Term effects of cannabis on brain structure. Neuropsychopharmacology 39: 2041-2048.
4. Belue RC, Howlett AC, Westlake TM, Hutchings DE (1995). The ontogeny of cannabinoid receptors in the brain of postnatal and aging rats. Neurotoxicol Teratol 17: 25-30.
5. Biscaia M, Fernandez B, Higuera-Matas A, Miguens M, Viveros MP, Garcia-Lecumberri C et al (2008). Sex-dependent effects of periadolescent exposure to the cannabinoid agonist CP-55,940 on morphine self-administration behaviour and the endogenous opioid system. Neuropharmacology 54: 863-873.
6. Breivogel CS, Childers SR, Deadwyler SA, Hampson RE, Vogt LJ, Sim-Selley LJ (1999). Chronic delta9-tetrahydrocannabinol treatment produces a time-dependent loss of cannabinoid receptors and cannabinoid receptor-activated G proteins in rat brain. J Neurochem 73: 2447-2259.
7. Burns HD, Van LK, Sanabria-Bohorquez S, Hamill TG, Bormans G, Eng WS et al (2007).[18F]MK-9470, a positron emission tomography (PET) tracer for in vivo human PET brain imaging of the cannabinoid-1 receptor. Proc Natl Acad Sci USA 104: 9800-9805.
8. Cadoni C, Simola N, Espa E, Fenu S, Di Chiara G (2013). Strain dependence of adolescent Cannabis influence on heroin reward and mesolimbic dopamine transmission in adult Lewis and Fischer 344 rats. Addict Biol 20: 132-142.
9. Chadwick B, Miller ML, Hurd YL (2013). Cannabis use during adolescent development: susceptibility to psychiatric illness. Front Psychiatry 4: 129.
10. Chen CY, O'Brien MS, Anthony JC (2005). Who becomes cannabis dependent soon after onset of use? Epidemiological evidence from the United States: 2000-2001. Drug Alcohol Depend 79: 11-22.
11. Chen CY, Storr CL, Anthony JC (2009). Early-onset drug use and risk for drug dependence problems. Addict Behav 34: 319-322.
12. Coffey C, Carlin JB, Lynskey M, Li N, Patton GC (2003). Adolescent precursors of cannabis dependence: findings from the Victorian Adolescent Health Cohort Study. Br J Psychiatry 182: 330-336.
13. Copeland J, Swift W (2009). Cannabis use disorder: epidemiology and management. Int Rev Psychiatry 21: 96-103.
14. Deiana S, Fattore L, Spano MS, Cossu G, Porcu E, Fadda P et al (2007). Strain and schedule-dependent differences in the acquisition, maintenance and extinction of intravenous cannabinoid selfadministration in rats. Neuropharmacology 52: 646-654.
15. Ellgren M, Artmann A, Tkalych O, Gupta A, Hansen HS, Hansen SH et al (2008). Dynamic changes of the endogenous cannabinoid and opioid mesocorticolimbic systems during adolescence: THC effects. Eur Neuropsychopharmacol 18: 826-834.
16. Ellgren M, Hurd YL, Franck J (2004). Amphetamine effects on dopamine levels and behavior following cannabinoid exposure during adolescence. Eur J Pharmacol 497: 205-213.
17. Ellgren M, Spano SM, Hurd YL (2007). Adolescent cannabis exposure alters opiate intake and opioid limbic neuronal populations in adult rats. Neuropsychopharmacology 32: 607-615.
18. Fadda P, Scherma M, Spano MS, Salis P, Melis V, Fattore L et al (2006). Cannabinoid self-administration increases dopamine release in the nucleus accumbens. Neuroreport 17: 1629-1632.
19. Fattore L, Cossu G, Martellotta CM, Fratta W (2001). Intravenous self-administration of the cannabinoid CB1 receptor agonist WIN 55,212-2 in rats. Psychopharmacology 156: 410-416.
20. Fattore L, Spano MS, Altea S, Angius F, Fadda P, Fratta W (2007). Cannabinoid self-administration in rats: sex differences and the influence of ovarian function. Br J Pharmacol 152: 795-804.
21. Fergusson DM, Boden JM (2008). Cannabis use and later life outcomes. Addiction 103: 969-976.
22. Fergusson DM, Boden JM, Horwood LJ (2006). Cannabis use and other illicit drug use: testing the cannabis gateway hypothesis. Addiction 101: 556-566.
23. Fergusson DM, Horwood LJ, Lynskey MT, Madden PA (2003). Early reactions to cannabis predict later dependence. Arch Gen Psychiatry 60: 1033-1039.
24. French ED, Dillon K, Wu X (1997). Cannabinoids excite dopamine neurons in the ventral tegmentum and substantia nigra. Neuroreport 8: 649-652.
25. Galve-Roperh I, Palazuelos J, Aguado T, Guzmán M (2009). The endocannabinoid system and the regulation of neural development: potential implications in psychiatric disorders. Eur Arch Psychiatry Clin Neurosci 259: 371-382.
26. Gessa GL, Melis M, Muntoni AL, Diana M (1998). Cannabinoids activate mesolimbic dopamine neurons by an action on cannabinoid CB1 receptors. Eur J Pharmacol 341: 39-44.
27. Gilman JM, Kuster JK, Lee S, Lee MJ, Kim BW, Makris N et al (2014). Cannabis use is quantitatively associated with nucleus accumbens and amygdala abnormalities in young adult recreational users. J Neurosci 34: 5529-5558.
28. Gray KM (2013). New developments in understanding and treating adolescent marijuana dependence. Adolesc Psychiatry 3: 297-306.
29. Higuera-Matas A, Soto-Montenegro ML, del Olmo N, Miguens M, Torres I, Vaquero JJ et al (2008). Augmented acquisition of cocaine self-administration and altered brain glucose metabolism in adult female but not male rats exposed to a cannabinoid agonist during adolescence. Neuropsychopharmacology 33: 806-813.
30. Hurd YL, Michaelides M, Miller ML, Jutras-Aswad D (2014). Trajectory of adolescent cannabis use on addiction vulnerability. Neuropharmacology 76: 416-424.
31. Justinova Z, Mascia P, Wu HQ, Secci ME, Redhi GH, Panlilio LV et al (2013). Reducing cannabinoid abuse and preventing relapse by enhancing endogenous brain levels of kynurenic acid. Nat Neurosci 16: 1652-1661.
32. Kandel D (1975). Stages in adolescent involvement in drug use. Science 190: 912-914.
33. Keeley RJ, Trow J, McDonald RJ (2015). Strain and sex differences in puberty onset and the effects of THC administration on weight gain and brain volumes. Neuroscience 305: 328-342.
34. Lammel S, Lim BK, Malenka RC (2014). Reward and aversion in a heterogeneous midbrain dopamine system. Neuropharmacology 76: 351-359.
35. Lecca S, Melis M, Luchicchi A, Muntoni AL, Pistis M (2012). Inhibitory inputs from rostromedial tegmental neurons regulate spontaneous activity of midbrain dopamine cells and their responses to drugs of abuse. Neuropsychopharmacology 37: 1164-1176.
36. Mackie K (2005). Distribution of cannabinoid receptors in the central and peripheral nervous system. Handb Exp Pharmacol 168: 299-325.
37. McLaughlin CR, Martin BR, Compton DR, Abood ME (1994). Cannabinoid receptors in developing rats: detection of mRNA and receptor binding. Drug Alcohol Depend 36: 27-31.
38. Melis M, De Felice M, Lecca S, Fattore L, Pistis M (2013). Sex-specific tonic 2-arachidonoylglycerol signaling at inhibitory inputs onto dopamine neurons of Lister Hooded rats. Front Integr Neurosci 7: 93.
39. Meye FJ, Adan RA (2014). Feelings about food: the ventral tegmental area in food reward and emotional eating. Trends Pharmacol Sci 35: 31-40.
40. Morel LJ, Giros B, Dauge V (2009). Adolescent exposure to chronic delta-9-tetrahydrocannabinol blocks opiate dependence in maternally deprived rats. Neuropsychopharmacology 34: 2469-2476.
41. Paxinos G, Watson C (1998). The Rat Brain in Stereotaxic Coordinates. Academic Press: San Diego, CA, USA.
42. Pistis M, Perra S, Pillolla G, Melis M, Muntoni AL, Gessa GL (2004). Adolescent exposure to cannabinoids induces long-lasting changes in the response to drugs of abuse of rat midbrain dopamine neurons. Biol Psychiatry 56: 86-94.
43. Quinn HR, Matsumoto I, Callaghan PD, Long LE, Arnold JC, Gunasekaran N et al (2008). Adolescent rats find repeated Delta(9)-THC less aversive than adult rats but display greater residual cognitive deficits and changes in hippocampal protein expression following exposure. Neuropsychopharmacology 33: 1113-1126.
44. Rice D, Barone S Jr (2000). Critical periods of vulnerability for the developing nervous system: evidence from humans and animal models. Environ Health Perspect 108: 511-533.
45. Rodriguez de Fonseca F, Ramos JA, Bonnin A, Fernández-Ruiz JJ (1993). Presence of cannabinoid binding sites in the brain from early postnatal ages. Neuroreport 4: 135-138.
46. Rodríguez-Arias M, Manzanedo C, Roger-Sánchez C, Do Couto BR, Aguilar MA, Minãrro J (2010). Effect of adolescent exposure to WIN 55212-2 on the acquisition and reinstatement of MDMAinduced conditioned place preference. Prog Neuropsychopharmacol Biol Psychiatry 34: 166-171.
47. Romero J, Berrendero F, Garciá-Gil L, Ramos JA, Fernández-Ruiz JJ (1998). Cannabinoid receptor and WIN-55,212-2-stimulated [35S]GTP gamma S binding and cannabinoid receptor mRNA levels in the basal ganglia and the cerebellum of adult male rats chronically exposed to delta 9-tetrahydrocannabinol. J Mol Neurosci 11: 109-119.
48. Rubino T, Parolaro D (2014). Cannabis abuse in adolescence and the risk of psychosis: a brief review of the preclinical evidence. Prog Neuropsychopharmacol Biol Psychiatry 52: 41-44.
49. Rubino T, Patrini G, Parenti M, Massi P, Parolaro D (1997). Chronic treatment with a synthetic cannabinoid CP-55,940 alters G-protein expression in the rat central nervous system. Brain Res Mol Brain Res 44: 191-197.
50. Rubino T, Vigano' D, Realini N, Guidali C, Braida D, Capurro V et al (2008). Chronic delta 9-tetrahydrocannabinol during adolescence provokes sex-dependent changes in the emotional profile in adult rats: behavioral and biochemical correlates. Neuropsychopharmacology 33: 2760-2771.
51. Rubino T, Zamberletti E, Parolaro D (2012). Adolescent exposure to cannabis as a risk factor for psychiatric disorders. J Psychopharmacol 26: 177-188.
52. Schneider M (2013). Adolescence as a vulnerable period to alter rodent behavior. Cell Tissue Res 354: 99-106.
53. Schneider M, Koch M (2003). Chronic pubertal, but not adult chronic cannabinoid treatment impairs sensorimotor gating, recognition memory and the performance in a progressive ratio task in adult rats. Neuropsychopharmacology 28: 1760-1769.
54. Solinas M, Goldberg SR, Piomelli D (2008). The endocannabinoid system in brain reward processes. Br J Pharmacol 154: 369-383.
55. Spano MS, Fadda P, Frau R, Fattore L, Fratta W (2010). Cannabinoid self-administration attenuates PCP-induced schizophrenia-like symptoms in adult rats. Eur Neuropsychopharmacol 20: 25-36.
56. Spano MS, Fattore L, Cadeddu F, Fratta W, Fadda P (2013). Chronic cannabinoid exposure reduces phencyclidine-induced schizophrenia-like positive symptoms in adult rats. Psychopharmacology 225: 531-542.
57. Stiglick A, Kalant H (1983). Behavioral effects of prolonged administration of delta 9-tetrahydrocannabinol in the rat. Psychopharmacology 80: 325-330.
58. Stopponi S, Soverchia L, Ubaldi M, Cippitelli A, Serpelloni G, Ciccocioppo R (2013). Chronic THC during adolescence increases the vulnerability to stress-induced relapse to heroin seeking in adult rats. Eur Neuropsychopharmacol 24: 1037-1045.
59. Tanda G, Pontieri FE, Di Chiara G (1997). Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism. Science 276: 2048-2050.
60. Tomasiewicz HC, Jacobs MM, Wilkinson MB, Wilson SP, Nestler EJ, Hurd YL (2012). Proenkephalin mediates the enduring effects of adolescent cannabis exposure associated with adult opiate vulnerability. Biol Psychiatry 72: 803-810.
61. Ungless MA, Grace AA (2012). Are you or aren't you? Challenges associated with physiologically identifying dopamine neurons. Trends Neurosci 35: 422-430.
62. UNODC (2014). United Nations Office on Drugs and Crime: World Drug Report 2014.
63. Urban NB, Slifstein M, Thompson JL, Xu X, Girgis RR, Raheja S et al (2012). Dopamine release in chronic cannabis users: a [11c] raclopride positron emission tomography study. Biol Psychiatry 71: 677-683.
64. Viveros MP, Llorente R, Suarez J, Llorente-Berzal A, López-Gallardo M, de Fonseca FR (2012). The endocannabinoid system in critical neurodevelopmental periods: sex differences and neuropsychiatric implications. J Psychopharmacol 26: 164-176.